REGENXBIO Inc.
AAV gene-therapy company advancing late-stage programs in Duchenne muscular dystrophy, retinal disease and rare genetic disorders.
Neuromuscular, retinal & rare genetic disease · AAV gene therapy · Pivotal / BLA planned Q3 2026
AAV gene-therapy company advancing late-stage programs in Duchenne muscular dystrophy, retinal disease and rare genetic disorders.
Neuromuscular, retinal & rare genetic disease · AAV gene therapy · Pivotal / BLA planned Q3 2026